Brain research · 2025
Optimized dose of hydrogen-enriched water with minocycline combination therapy in experimental ischemic stroke.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Zhao, Alamuri Tharun T, Yang Darren L, Annarino Tyler, Muir Eric R, Duong Tim Q
Аннотация
BACKGROUND: Ischemic stroke remains a leading cause of death and disability worldwide, with limited effective treatments due to the complexity of its pathophysiology. Molecular hydrogen (H2) and minocycline (M), both possessing anti-inflammatory and antioxidant properties, have shown individual neuroprotective potential in preclinical models. However, the optimal therapeutic dosing of H2, particularly in combination with other agents, remains undefined.
OBJECTIVE: This study aimed to (1) determine the dose-response relationship of hydrogen-enriched water in a rat model of transient middle cerebral artery occlusion (MCAO), and (2) evaluate whether optimized H2 dosing combined with minocycline provides superior neuroprotection compared to H2 monotherapy.
METHODS: Sixty-six male and female Sprague-Dawley rats underwent 60-minute MCAO followed by treatment with varying doses (5-30 mL/kg) of hydrogen-enriched water (3.2 ppm), alone or in combination with minocycline (20 mg/kg). Treatments were administered post-reperfusion as well as on days 1 and 2. Behavioral outcomes (Garcia score) and infarct volumes (TTC staining) were assessed at 7 days post-stroke.
RESULTS: The optimal H2 dose was 20 mL/kg, which produced the highest Garcia scores and lowest infarct volumes. A dose-dependent effect was observed with a quadratic fit (R2 = 0.751 for Garcia scores; R2 = 0.289 for lesion volume). Combination therapy with H2 and minocycline significantly outperformed H2 monotherapy in both neurological recovery and infarct reduction, with no sex differences observed.
CONCLUSION: Hydrogen-enriched water shows a dose-dependent neuroprotective effect in experimental ischemic stroke, with 20 mL/kg identified as the optimal dose. Combined therapy with minocycline further enhances outcomes, supporting the potential of dual-agent strategies for improved stroke treatment. These findings provide a foundation for translational development of H2-based combination therapies in clinical settings.
OBJECTIVE: This study aimed to (1) determine the dose-response relationship of hydrogen-enriched water in a rat model of transient middle cerebral artery occlusion (MCAO), and (2) evaluate whether optimized H2 dosing combined with minocycline provides superior neuroprotection compared to H2 monotherapy.
METHODS: Sixty-six male and female Sprague-Dawley rats underwent 60-minute MCAO followed by treatment with varying doses (5-30 mL/kg) of hydrogen-enriched water (3.2 ppm), alone or in combination with minocycline (20 mg/kg). Treatments were administered post-reperfusion as well as on days 1 and 2. Behavioral outcomes (Garcia score) and infarct volumes (TTC staining) were assessed at 7 days post-stroke.
RESULTS: The optimal H2 dose was 20 mL/kg, which produced the highest Garcia scores and lowest infarct volumes. A dose-dependent effect was observed with a quadratic fit (R2 = 0.751 for Garcia scores; R2 = 0.289 for lesion volume). Combination therapy with H2 and minocycline significantly outperformed H2 monotherapy in both neurological recovery and infarct reduction, with no sex differences observed.
CONCLUSION: Hydrogen-enriched water shows a dose-dependent neuroprotective effect in experimental ischemic stroke, with 20 mL/kg identified as the optimal dose. Combined therapy with minocycline further enhances outcomes, supporting the potential of dual-agent strategies for improved stroke treatment. These findings provide a foundation for translational development of H2-based combination therapies in clinical settings.